http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#Head
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#assertion
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#provenance
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#pubinfo
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#assertion
http://purl.obolibrary.org/obo/DOID_10763
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_10763
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB01197
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#association
http://www.w3.org/2000/01/rdf-schema#label
captopril tablets usp are indicated for the treatment of hypertension hypertension in using captopril consideration should be given to the risk of neutropenia agranulocytosis see warnings captopril may be used as initial therapy for patients with normal renal function in whom the risk is relatively low in patients with impaired renal function particularly those with collagen vascular disease captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs or have failed to respond satisfactorily to drug combinations captopril is effective alone and in combination with other antihypertensive agents especially thiazide type diuretics the blood pressure lowering effects of captopril and thiazides are approximately additive captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis the beneficial effect of captopril in heart failure does not require the presence of digitalis however most controlled clinical trial experience with captopril has been in patients receiving digitalis as well as diuretic treatment heart failure captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction 4 and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients left ventricular dysfunction after myocardial infarction captopril tablets are indicated for the treatment of diabetic nephropathy proteinuria 5 mg day in patients with type i insulin dependent diabetes mellitus and retinopathy captopril tablets decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes death or need for renal transplantation or dialysis diabetic nephropathy in considering use of captopril tablets it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in non blacks in addition ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in non black patients see warnings angioedema
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB01197
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#provenance
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#pubinfo
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#sig
http://purl.org/nanopub/x/hasSignature
bWWrGbKtB6HYf1czerCGKzKzIIHArTeTGbbuIjEAvoUfE5c5eu6oAfHpVUBqDXuzg//eiRU/hdoI+bPAOwuGDSEIOsJiGJCne59r3GSsrMZIsdcPVkowBly9Aggjbgv6T3KiFlbeflqCwvxoEa1SGwoAiMP0/CBz05CZGmo/sl4=
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY
http://purl.org/dc/terms/created
2021-06-15T18:41:02.353+02:00
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs